ATE388961T1 - Verfahren zur identifikation von inhibitoren - Google Patents

Verfahren zur identifikation von inhibitoren

Info

Publication number
ATE388961T1
ATE388961T1 AT04775932T AT04775932T ATE388961T1 AT E388961 T1 ATE388961 T1 AT E388961T1 AT 04775932 T AT04775932 T AT 04775932T AT 04775932 T AT04775932 T AT 04775932T AT E388961 T1 ATE388961 T1 AT E388961T1
Authority
AT
Austria
Prior art keywords
apobec3g
vif
degradation
binds
inhibit
Prior art date
Application number
AT04775932T
Other languages
English (en)
Inventor
David Kabat
Mariana Marin
Susan Kozak
Kristine Rose
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE388961(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Application granted granted Critical
Publication of ATE388961T1 publication Critical patent/ATE388961T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16HIV-1, HIV-2
    • G01N2333/163Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04775932T 2003-05-23 2004-05-03 Verfahren zur identifikation von inhibitoren ATE388961T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47335703P 2003-05-23 2003-05-23

Publications (1)

Publication Number Publication Date
ATE388961T1 true ATE388961T1 (de) 2008-03-15

Family

ID=34272433

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775932T ATE388961T1 (de) 2003-05-23 2004-05-03 Verfahren zur identifikation von inhibitoren

Country Status (6)

Country Link
US (1) US7220554B2 (de)
EP (1) EP1629003B1 (de)
AT (1) ATE388961T1 (de)
CA (1) CA2525972A1 (de)
DE (1) DE602004012406T2 (de)
WO (1) WO2005024422A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068676A2 (en) * 2001-02-27 2002-09-06 University Of Rochester METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING
EP1575992A4 (de) * 2002-08-05 2007-02-21 Univ Rochester Chimäre proteine aus proteintransduzierender domäne/deaminase, verwandte verbindungen und deren verwendungen
GB0228429D0 (en) * 2002-12-05 2003-01-08 Novartis Ag Organic compounds
ATE506456T1 (de) * 2003-06-10 2011-05-15 David Gladstone Inst Verfahren zur behandlung von lentivirusinfektionen
CA2537798A1 (en) * 2003-09-03 2005-03-17 University Of Rochester Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
WO2005047476A2 (en) * 2003-11-10 2005-05-26 Rigel Pharmaceuticals, Inc. Inhibition of retroviral replication through modulation of the host cell ubiquitylation
WO2005077105A2 (en) * 2004-02-11 2005-08-25 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of hiv-1 replication by a mutant apolipoprotein b mrna editing enzyme-catalytic polypeptide-like 3 g (apobec3g)
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US8133666B2 (en) * 2004-11-02 2012-03-13 The J. David Gladstone Institutes Method for identifying agents capable of inhibiting APOBEC3C activity in HIV-infected cells
CA2596448A1 (en) * 2005-02-11 2006-08-11 University Of Rochester Methods and compositions related to heightened apobec-1 related protein (arp) expression
TWI294036B (en) * 2005-02-24 2008-03-01 Tzu Chi Buddhist General Hospital A method for screening compounds against flaviviruses infection by using persistent virus-infected cell systems
CA2599525C (en) * 2005-03-08 2015-05-26 Molmed Spa Hiv vif
WO2007147714A1 (en) * 2006-06-23 2007-12-27 Basell Poliolefine Italia S.R.L. Magnesium chloroalkolate-based catalyst precursors
US8338089B2 (en) * 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
US7803582B2 (en) * 2007-03-17 2010-09-28 Hongzhan Xu Recombinant vector and use in gene therapy
US20090176202A1 (en) * 2007-03-23 2009-07-09 Rigel Pharmaceuticals, Inc. Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIV
EP2025750B1 (de) 2007-08-13 2011-12-28 Nexigen GmbH Targets und Zusammensetzungen zur therapeutischen Intervention bei HIV-Infektion
US20090075309A1 (en) * 2007-09-06 2009-03-19 Gambhir Sanjiv S Bisdeoxycoelenterazine derivatives, methods of use, and BRET2 systems
US20120271036A1 (en) * 2009-10-29 2012-10-25 University Of Rochester Solution Assay and High Through-Put Screen to Probe Interaction Between Human Cullin-Ring Ligase Complex and HIV-VIF Protein
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
FR2973040B1 (fr) * 2011-03-23 2016-04-15 Centre Nat De La Rech Scient (C N R S) Methode de criblage de composes antiretroviraux et vaccin
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3077417A1 (de) * 2013-12-08 2016-10-12 Peptcell Limited Hiv-antigene und antikörper und zusammensetzungen, verfahren und verwendungen davon
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
WO2023089808A1 (ja) * 2021-11-22 2023-05-25 隆英 河野 APOBEC3G/Vif結合体形成阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7568794A (en) 1993-08-20 1995-03-21 St. Luke's-Roosevelt Hospital Center Hiv (vif)-related compositions, and prophylactic and therapeutic uses thereof
US6360178B1 (en) * 1997-12-09 2002-03-19 Antony Cozart Parsons System and method for locating a disturbance in a power system based upon disturbance power and energy
WO2000058480A1 (en) 1999-03-29 2000-10-05 Kansai Technology Licensing Organization Co., Ltd. Novel cytidine deaminase
EP1373308B1 (de) * 2001-04-06 2006-10-25 Thomas Jefferson University Antagonist für die multimerisierung von hiv-1 vif-protein
AU2003229998A1 (en) 2002-05-10 2003-11-11 Medical Research Council Activation induced deaminase (aid)
US20040009951A1 (en) * 2002-06-13 2004-01-15 Malim Michael H DNA deamination mediates innate immunity to (retro)viral infection
EP1575992A4 (de) 2002-08-05 2007-02-21 Univ Rochester Chimäre proteine aus proteintransduzierender domäne/deaminase, verwandte verbindungen und deren verwendungen

Also Published As

Publication number Publication date
EP1629003A2 (de) 2006-03-01
US20040234956A1 (en) 2004-11-25
WO2005024422A2 (en) 2005-03-17
DE602004012406T2 (de) 2009-04-30
CA2525972A1 (en) 2005-03-17
US7220554B2 (en) 2007-05-22
DE602004012406D1 (de) 2008-04-24
EP1629003B1 (de) 2008-03-12
WO2005024422A3 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE388961T1 (de) Verfahren zur identifikation von inhibitoren
Strebel HIV accessory proteins versus host restriction factors
ATE505475T1 (de) Nukleosidderivate als inhibitoren viraler polymerasen
EA200801025A1 (ru) Композиция и синтез новых реагентов для ингибирования репликации вич
EA200970050A1 (ru) Ингибиторы пролилгидроксилаз
EA200701771A1 (ru) Низкомолекулярные ингибиторы mdm2 и их применение
EA200701204A1 (ru) Калиевая соль ингибитора вич-интегразы
EA201301284A1 (ru) Способ получения соединений, являющихся ингибиторами вирусной полимеразы и способ получения фармацевтических композиций, а также промежуточные соединения
DK1427817T3 (da) Formering af vira i cellekultur
NO20073396L (no) Farmasoytiske kombinasjoner av en angiotensinreceptorantagonist og en NEP-inhibitor
EA200900360A1 (ru) Новые низкомолекулярные ингибиторы mdm2 и их применение
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
EA200700243A1 (ru) Способы лечения гепатита с
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
EA201000366A1 (ru) Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
EA201001508A1 (ru) Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич
EP1735465A4 (de) Zusammensetzungen zur verwendung bei der bestimmung von hämorrhagischen fieberviren
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
ATE553764T1 (de) Zusammensetzungen und verfahren zur identifizierung von inhibitoren einer retrovirusinfektion
ATE411030T1 (de) Phosphonatanaloga von hiv- integrasehemmerverbindungen
EA201101397A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CL2008002291A1 (es) Compuestos derivados del acido 4-fluor-benzoico, inhibidores de la polimerasa hcv, composicion farmaceutica, kit farmaceutico y su uso para el tratamiento de una infeccion viral por hepatitis c.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties